K10.9
Conditions
Interventions
Group 1: Patients who received Straumann implants between 2006 and 2020 at the clinics of conservative and preventive and reconstructive dentistry of the Center of Dental Medicine of the University of
Sponsors
ZZM
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - The patient received a dental implant between 2006 and 2020. - Straumann implants were used in the posterior area (premolars and molars, maxilla or mandible) with screw-retained single-tooth crowns or bridges in healed sites. - BL implants were placed exactly at bone level, while TL implants had the polished part positioned outside the bone. - The patient was treated without bone augmentation or soft-tissue augmentation. - X-rays were taken before surgery and at least 12 months after prosthetic rehabilitation. - Age = 18 years - Signed informed consent or exception permit (in relation to HRA Art. 34) by the ethics committee ZH
Exclusion criteria
Exclusion criteria: - Immediate implant placement - Cemented restorations - Radiotherapy in the head and neck area in the past - Systemic or localised diseases or conditions that may impair healing or osseointegration (e.g. diabetes, osteoporosis, ...) - use of drugs that impact bone metabolism - Severe bruxism - Clear signs of implant malposition or prosthetic misfit - Implants with extending cantilevers - Mucosal height that cannot be measured - Implants that have undergone one- or two-stage bone augmentation - Mucogingival surgery with the aim of increasing the width of the attached mucosa - Mucogingival surgery to thicken the mucosa - Implants without regular individual patient-orientated supportive periodontal care - Presence of a documented refusal or revocation of consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in radiographic detectable amount of marginal bone loss one year (T1), three years (T2) and five years (T3) after implant placement (compared to marginal bone level at T0). These differences in marginal bone loss will be investigated in view of supracrestal tissue height (STH), implant type, age, smoking, gender, type of reconstruction, compliance, history of periodontitis, emergence angle and jaw of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| there is no secondary outcome | — |
Countries
Switzerland
Contacts
Public ContactPatrick Schmidlin
ZZM
Outcome results
None listed